Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 19, 2013

View Archived Issues

Novel aminoglycoside antibiotic shows anti-MRSA activity with reduced nephrotoxicity

CETP inhibitors for the treatment of atherosclerosis

Smallpox vaccine CJ-50300 safe in phase III trial

Novan compares activity of Nitricil compounds against Staphylococcus aureus

Acacia Pharma initiates phase III studies of APD-421 for PONV

Regado Biosciences begins phase III trial of pegnivacogin/anivamersen

PeptiDream licenses PDPS technology to Bristol-Myers Squibb

AGE receptors identified in human osteoarthritic cartilage

Agenus reports follow-on phase II data for brain cancer vaccine

Third review also recommends PreSERVE AMI study continuation

Repros Therapeutics reports Androxal study data

BioCryst awarded NIAID contract to combat Marburg virus hemorrhagic fever

Eslicarbazepine acetate meets primary endpoint in two phase III epilepsy studies

GW Pharmaceuticals begins phase I study of cannabinoid GWP-42006 for epilepsy

Profectus BioSciences begins phase I trial of HIV plasmid DNA vaccine

H3 Biomedicine and Selvita establish strategic collaboration in oncology

Compugen reports data on immune checkpoint protein CGEN-15049

Rottapharm patents novel orexin OX1 receptor antagonists

FORMA Therapeutics and Genentech disclose Nampt inhibitors

PIQUR Therapeutics plans phase I study of PQR-309

Takeda designs series of MetAP 2 inhibitors

Allergan synthesizes series of chemokine CCR2 receptor antagonists

ChemoCentryx regains rights to vercirnon from GlaxoSmithKline

Mitsubishi Tanabe Pharma acquires Medicago

CE mark granted to Abbott's FreeStyle Optium Neo Blood Glucose and Ketone Monitoring System

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.